Heron Therapeutics Inc. (NASDAQ:HRTX) was up 4.9% during mid-day trading on Friday . The company traded as high as $17.45 and last traded at $17.25, with a volume of 319,375 shares. The stock had previously closed at $16.44.

A number of equities research analysts have issued reports on HRTX shares. Cantor Fitzgerald reiterated a “buy” rating and issued a $41.00 target price on shares of Heron Therapeutics in a research report on Friday, June 24th. Leerink Swann restated a “buy” rating on shares of Heron Therapeutics in a research note on Monday, June 27th. Brean Capital restated a “buy” rating on shares of Heron Therapeutics in a research note on Monday, April 18th. Jefferies Group restated a “buy” rating on shares of Heron Therapeutics in a research note on Thursday, April 28th. Finally, Noble Financial restated a “buy” rating and set a $51.00 price target on shares of Heron Therapeutics in a research note on Wednesday, April 20th. One analyst has rated the stock with a sell rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. Heron Therapeutics currently has an average rating of “Buy” and an average target price of $51.50.

The stock’s 50-day moving average price is $18.59 and its 200-day moving average price is $19.68.

Heron Therapeutics (NASDAQ:HRTX) last issued its earnings results on Thursday, May 5th. The biotechnology company reported ($0.92) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.92). On average, equities analysts predict that Heron Therapeutics Inc. will post ($3.59) earnings per share for the current year.

In related news, President Robert Rosen sold 200,000 shares of the business’s stock in a transaction on Thursday, April 21st. The shares were sold at an average price of $23.23, for a total transaction of $4,646,000.00. Following the transaction, the president now directly owns 178,968 shares in the company, valued at $4,157,426.64. The sale was disclosed in a filing with the SEC, which is available through this link.

A number of institutional investors have recently modified their holdings of the company. Swiss National Bank purchased a new position in shares of Heron Therapeutics during the fourth quarter worth $1,100,000. GAM Holding AG increased its position in shares of Heron Therapeutics by 28.9% in the fourth quarter. GAM Holding AG now owns 41,900 shares of the biotechnology company’s stock worth $1,119,000 after buying an additional 9,400 shares during the last quarter. Russell Frank Co increased its position in shares of Heron Therapeutics by 46.9% in the fourth quarter. Russell Frank Co now owns 48,830 shares of the biotechnology company’s stock worth $1,369,000 after buying an additional 15,585 shares during the last quarter. California State Teachers Retirement System increased its position in shares of Heron Therapeutics by 1.9% in the fourth quarter. California State Teachers Retirement System now owns 54,211 shares of the biotechnology company’s stock worth $1,447,000 after buying an additional 1,000 shares during the last quarter. Finally, California Public Employees Retirement System increased its position in shares of Heron Therapeutics by 863.8% in the fourth quarter. California Public Employees Retirement System now owns 90,600 shares of the biotechnology company’s stock worth $2,419,000 after buying an additional 81,200 shares during the last quarter.

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.